Trial · NCT02410343
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Body Fat Mass at Baseline, Week 24 and Endpoint in Core Period | Baseline (Day 1, pre-dose), Week 24, Endpoint in Core period | ITT | kg | MEAN |
| SECONDARY | Total Trunk Fat at Baseline, Week 24 and Endpoint in Core Period | Baseline (Day 1, pre-dose), Week 24, Endpoint in Core Period | ITT | kg | MEAN |
| SECONDARY | Insulin-Like Growth Factor 1 Standard Deviation Score (IGF-I SDS) at Baseline, Week 24 and Endpoint in Core Period | Baseline (Day 1, pre-dose), Week 24, Endpoint in Core Period | ITT | standard deviation score | MEAN |
| SECONDARY | Scored Analysis of Quality of Life Assessment of GH Deficiency in Adults (QoL-AGHDA) at Baseline, Week 24 and Endpoint in Core Period | Baseline (Day 1, pre-dose), Week 24, Endpoint in Core Period | ITT | units on a scale | MEAN |
| SECONDARY | Participants With Adverse Events During the Core Period | Day 1 up to 24 Weeks | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Participants With Potentially Clinically Significant Abnormal Blood and Urine Test Results | Day 1 up to 24 Weeks | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Shift From Baseline To Endpoint in Core Period in Electrocardiogram Findings | Day 1 up to Week 24 | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Thyroid Stimulating Hormone (TSH) at Baseline and Endpoint | Baseline (Day 1, pre-dose), Endpoint (up to Week 24) | Safety population of participants reporting data | MIU/L | MEAN |
| SECONDARY | Free Thyroxin (Free T4) at Baseline and Endpoint | Baseline (Day 1, pre-dose), Endpoint (up to Week 24) | Safety population of participants reporting data | PMOL/L | MEAN |
| SECONDARY | Triiodothyronine (Total T3) at Baseline and Endpoint | Baseline (Day 1, pre-dose), Endpoint (up to Week 24) | Safety population of participants reporting data | NMOL/L | MEAN |
| SECONDARY | Glycated Hemoglobin (HbA1c) at Baseline and Endpoint | Baseline (Day 1, pre-dose), Endpoint (up to Week 24) | Safety population of participants reporting data | percentage of total hemoglobin | MEAN |
| SECONDARY | Fasting Blood Glucose at Baseline and Endpoint | Baseline (Day 1, pre-dose), Endpoint (up to Week 24) | Safety population of participants reporting data | MMOL/L | MEAN |
| SECONDARY | Insulin at Baseline and Endpoint | Baseline (Day 1, pre-dose), Endpoint (up to Week 24) | Safety population of participants reporting data | PMOL/L | MEAN |
| SECONDARY | Local Tolerability Assessed by Injection Site Reactions | Daay 1 up to Week 24 | Safety population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Pharmacokinetic Serum Concentration of TV1106 by Nominal Sampling Timepoints | Baseline (Day 1, pre-dose), Weeks 4, 8, 12, 16, 24 | Safety population of participants treated with TV1106 | ng/mL | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02410343/outcomes